Emergent BioSolutions Reports First Quarter 2015 Financial

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Emergent BioSolutions Reports First Quarter 2015 Financial Results

GAITHERSBURG, Md., May 7, 2015 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) reported financial results for the quarter ended March 31, 2015.

Financial highlights for Q1 2015 include:

  • Total revenues of $63.6 million, up 18% versus Q1 2014
  • Net loss of $21.5 million, or $0.57 per diluted share; Adjusted net loss of $18.8 million, or $0.50 per diluted share
  • EBITDA of $(19.6) million, or $(0.52) per diluted share; Adjusted EBITDA of $(18.4) million, or $(0.48) per diluted share

2015 outlook:

  • FY 2015 total revenues of $510-$540 million, net income of $50-$60 million (GAAP) and $60-$70 million (adjusted)
  • Q2 2015 total revenues of $105 to $120 million

"Overall, our business performance in 2015 has been strong with FDA approvals of both Anthrasil and IXINITY, and initiating a Phase I trial for MOR209/ES414, our immunotherapeutic treatment for prostate cancer," said Daniel J. Abdun-Nabi, President and Chief Executive Officer of Emergent BioSolutions. "We anticipate full year revenues of $510 to $540 million, net income of $50 to $60 million and adjusted net income of $60 to $70 million, as we continue to expand the product portfolios of both of our businesses and drive robust growth in revenue and net income."

(I) 2015 FINANCIAL PERFORMANCE -- Quarter Ended March 31, 2015 (unaudited)

Revenues

Product Sales

For Q1 2015, product sales were $18.3 million, a decrease of 49% as compared to 2014. The decrease primarily reflects our decision to not make shipments of BioThrax to the CDC in the first quarter of 2015 due to the discovery of foreign particles in a limited number of vials in two manufactured lots of BioThrax in January 2015.

(in millions) Three Months Ended
  March 31,
  2015 2014 % Change
Product Sales      
BioThrax ® $ -- $24.5 (100)%
Other biodefense 11.9 8.1 47%
Total Biodefense $11.9 $32.6 (63)%
       
Total Biosciences 6.3 3.3 91%
Total Product Sales $18.3 $35.8 (49)%

Contract Manufacturing

For Q1 2015, revenues from our contract manufacturing operations were $12.2 million, an increase of $9.5 million as compared to 2014. The increase primarily reflects the impact of a full quarter of contract manufacturing activities, which were acquired in Q1 2014, as well as revenue for manufacturing services related to an MVA Ebola vaccine candidate.

Contracts, Grants and Collaborations

For Q1 2015, revenues from our contracts, grants and collaborations were $33.1 million, an increase of 115% as compared to 2014. The increase primarily reflects additional development funding for product development programs that were acquired in Q1 2014 and the realization of a milestone payment related to the development of a partnered product within the Biosciences division.

Operating Expenses

Cost of Product Sales and Contract Manufacturing

For Q1 2015, cost of product sales and contract manufacturing was $18.7 million, a decrease of 1% as compared to 2014.

Research and Development (R&D)

For Q1 2015, gross R&D expenses were $38.7 million, an increase of 28% as compared to 2014. The increase primarily reflects additional R&D expenditures associated with product development programs that were acquired in Q1 2014. Gross R&D expenses include contract service costs and development expenses related to product candidates, technology platforms and manufacturing capabilities in both the Biodefense and Biosciences divisions.

Net R&D expenses, which are more representative of the company's actual out-of-pocket investment in product development, are calculated as gross research and development expenses less contracts, grants and collaboration revenues. For Q1 2015, net R&D expenses were $5.6 million, a decrease of 62% as compared to 2014.

(in millions) Three Months Ended
  March 31,
  2015 2014 % Change
Research and Development Expenses (Gross) $38.7 $30.3 28%
Adjustments:
Contracts, grants and collaborations revenues 33.1 15.4 115%
Research and Development Expenses (Net) $5.6 $14.9 (62)%

Selling, General and Administrative

For Q1 2015, selling, general and administrative expenses were $34.5 million, an increase of 15% as compared to 2014. The increase primarily reflects additional post-acquisition selling, general and administrative costs that are largely associated with additional operations acquired in Q1 2014.

Net Loss (GAAP and Adjusted)

For Q1 2015, GAAP net loss was $21.5 million, or $0.57 per diluted share, as compared to a net loss of $20.2 million, or $0.55 per diluted share, in 2014. Q1 2015 adjusted net loss was $18.8 million, or $0.50 per diluted share, as compared to an adjusted net loss of $14.6 million, or $0.40 per diluted share, in 2014.

The following table provides a reconciliation of GAAP to Adjusted net loss for the three months ended March 31, 2015 and 2014.

(in millions, except per share price) Three Months Ended
  March 31,
  2015 2014 Source
GAAP Net Loss  $ (21.5)  $ (20.2) NA
Adjustments:      
Acquisition-related costs (transaction & integration) 1.1 4.2 SG&A
Non-cash amortization charges 2.6 1.6 COGS, SG&A, Other Income
Write off of syndicated loan fees -- 1.8 Other Income
Impact of purchase accounting on inventory step-up 0.1 0.4 COGS
Tax effect (1.1) (2.4) NA
Total Adjustments 2.7 5.6 NA
Adjusted Net Loss  $ (18.8)  $ (14.6) NA
Adjusted Net Loss Per Diluted Share  $ (0.50)  $ (0.40) NA

EBITDA and Adjusted EBITDA

For Q1 2015, earnings before interest, taxes, depreciation and amortization, or EBITDA, was $(19.6) million, or $(0.52) per diluted share, as compared to $(18.1) million, or $(0.49) per diluted share, in 2014. Adjusted EBITDA for Q1 2015 was $(18.4) million, or $(0.48) per diluted share, as compared to $(13.5) million, or $(0.37) per diluted share, in 2014.

The following table provides a reconciliation of GAAP Net Loss to EBITDA and Adjusted EBITDA for the three months ended March 31, 2015 and 2014.

(in millions, except per share price) Three Months Ended 
  March 31
  2015 2014
GAAP Net Loss  $ (21.5)  $ (20.2)
Adjustments:    
+ Depreciation & Amortization 8.5 6.8
- Benefit From Income Taxes (8.3) (8.2)
+ Interest Expense 1.7 3.5
Total Adjustments 1.9 2.1
EBITDA  $ (19.6)  $ (18.1)
EBITDA Per Diluted Share  $ (0.52)  $ (0.49)
Additional Adjustments:    
+ Acquisition-related costs (transaction & integration) 1.1 4.2
+ Impact of purchase accounting on inventory step-up 0.1 0.4
Total Additional Adjustments 1.2 4.6
Adjusted EBITDA  $ (18.4)  $ (13.5)
Adjusted EBITDA Per Diluted Share  $ (0.48)  $ (0.37)

Financial Condition and Liquidity

Cash and cash equivalents at March 31, 2015 were $216.5 million as compared to $280.5 million at December 31, 2014.

(II) 2015 FINANCIAL OUTLOOK

Full Year 2015

Factoring in the financial performance through the three months ended March 31, 2015, and expected performance through the remainder of the year, the company is reaffirming its full year 2015 financial outlook as follows:

(in millions) Twelve Months Ended
  December 31, 2015
  (Forecast)
Total Revenues $510 to $540
--  BioThrax Product Sales $270 to $285
Net Income (GAAP) $50 to $60
Net Income (Adjusted) $60 to $70

The company's outlook for 2015 does not include any estimates for potential new corporate development or other M&A transactions.

The following table provides a reconciliation of GAAP Net Income to Adjusted Net Income for the forecasted twelve month period of 2015.

(in millions) Financial Results for the
  Year Ended December 31,
  2015 Source
  (Forecast)  
GAAP Net Income $50.0 to $60.0 NA
Adjustments:    
Acquisition-related costs (transaction & integration) 2.0 SG&A
Non-cash amortization charges 11.0 COGS, SG&A, Other Income
Impact of purchase accounting on inventory step-up 1.0 COGS
Restructuring and other 1.0 SG&A
Tax effect (5.0) NA
Total Adjustments 10.0 NA
Adjusted Net Income $60.0 to $70.0 NA

Q2 2015

For the second quarter of 2015, the company anticipates total revenues of $105 to $120 million.

(III) RECONCILIATION OF GAAP NET INCOME TO ADJUSTED NET INCOME, GAAP NET LOSS TO ADJUSTED NET LOSS, EBITDA AND ADJUSTED EBITDA

This press release contains four financial measures (Adjusted Net Income, Adjusted Net Loss, EBITDA or earnings before interest, taxes, depreciation and amortization, and adjusted EBITDA) that are considered "non-GAAP" financial measures under applicable Securities & Exchange Commission rules and regulations. These non-GAAP financial measures should be considered supplemental to and not a substitute for financial information prepared in accordance with generally accepted accounting principles. The company's definition of these non-GAAP measures may differ from similarly titled measures used by others. Adjusted Net Income adjusts for specified items that can be highly variable or difficult to predict, or reflect the non-cash impact of charges resulting from purchase accounting. EBITDA reflects net income excluding the impact of depreciation, amortization, interest expense and provision for income taxes. Adjusted EBITDA also excludes specified items that can be highly variable and the non-cash impact of certain purchase accounting adjustments. The company views these non-GAAP financial measures as a means to facilitate management's financial and operational decision-making, including evaluation of the company's historical operating results and comparison to competitors' operating results. These non-GAAP financial measures reflect an additional way of viewing aspects of the company's operations that, when viewed with GAAP results and the reconciliations to the corresponding GAAP financial measure, may provide a more complete understanding of factors and trends affecting the company's business.

The determination of the amounts that are excluded from these non-GAAP financial measures are a matter of management judgment and depend upon, among other factors, the nature of the underlying expense or income amounts. Because non-GAAP financial measures exclude the effect of items that will increase or decrease the company's reported results of operations, management strongly encourages investors to review the company's consolidated financial statements and publicly filed reports in their entirety.

CONFERENCE CALL AND WEBCAST INFORMATION

Company management will host a conference call at 5:00 pm (Eastern Time) on Thursday, May 7, 2015 to discuss these financial results. This conference call can be accessed live by telephone or through Emergent's website:

Live Teleconference Information: Live Webcast Information:
Dial in number: 855-766-6521 Visit www.emergentbiosolutions.com
International dial in: 262-912-6157 and select the " Investors " section
Passcode: 27616485  
   
  Webcast Archive:
  Visit www.emergentbiosolutions.com
  and select the " Investors " section
  Available through May 7, 2016

ABOUT EMERGENT BIOSOLUTIONS INC.

Emergent BioSolutions is a specialty biopharmaceutical company seeking to protect and enhance life by offering specialized products to healthcare providers and governments to address medical needs and emerging health threats. Additional information about the company may be found at www.emergentbiosolutions.com . Follow us on twitter: @emergentbiosolu

SAFE HARBOR STATEMENT

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements, other than statements of historical fact, including our financial guidance, and any other statements containing the words "believes", "expects", "anticipates", "intends", "plans", "forecasts", "estimates" and similar expressions in conjunction with, among other things, discussions of financial performance or financial condition, growth strategy, product sales, manufacturing capabilities, product development, regulatory approvals or expenditures are forward-looking statements. These forward-looking statements are based on our current intentions, beliefs and expectations regarding future events. We cannot guarantee that any forward-looking statement will be accurate. Investors should realize that if underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could differ materially from our expectations. Investors are, therefore, cautioned not to place undue reliance on any forward-looking statement. Any forward-looking statement speaks only as of the date of this press release, and, except as required by law, we do not undertake to update any forward-looking statement to reflect new information, events or circumstances.

There are a number of important factors that could cause the company's actual results to differ materially from those indicated by such forward-looking statements, including appropriations for BioThrax procurement; our ability to perform under our contracts with the U.S. government related to BioThrax, including the timing of deliveries; our ability to obtain new BioThrax sales contracts or modifications to existing contracts; the availability of funding for our U.S. government grants and contracts; our ability to successfully execute our growth strategy and achieve our financial and operational goals; our ability to successfully integrate and develop the products or product candidates, programs, operations and personnel of any entities or businesses that we acquire; our ability to perform under our contract with the U.S. government to develop and obtain regulatory approval for large-scale manufacturing of BioThrax in Building 55, our large-scale vaccine manufacturing facility in Lansing, Michigan; our ability to identify and acquire companies or in-license products or late-stage product candidates that satisfy our selection criteria; our ability to realize synergies and benefits from acquisitions or in-licenses within expected time periods or at all; our ability to selectively enter into collaboration arrangements; our ability to achieve milestones in our out-license and collaboration contracts; our ability to obtain and maintain intellectual property protection for our products and product candidates; our ability and plans to expand our manufacturing facilities and capabilities; our ability and the ability of our contractors and suppliers to maintain compliance with cGMP and other regulatory obligations; the results of regulatory inspections; our ability to meet operating and financial restrictions placed on us and our subsidiaries under our senior secured credit facility; the rate and degree of market acceptance and clinical utility of our products; the success of our ongoing and planned development programs, non-clinical activities and clinical trials of our product candidates; the timing of and our ability to obtain and maintain regulatory approvals for our product candidates; the success of our commercialization, marketing and manufacturing capabilities and strategy; and the accuracy of our estimates regarding future revenues, expenses, capital requirements and needs for additional financing.

The foregoing sets forth many, but not all, of the factors that could cause actual results to differ from our expectations in any forward-looking statement. Investors should consider this cautionary statement, as well as the risk factors identified in our periodic reports filed with the SEC, when evaluating our forward-looking statements.

FINANCIAL STATEMENTS FOLLOW

Emergent BioSolutions Inc. and Subsidiaries
Consolidated Balance Sheets
(in thousands, except share and per share data)
     
  March 31, 2015 December 31, 2014
ASSETS (Unaudited)  
Current assets:    
Cash and cash equivalents  $ 216,515  $ 280,499
Accounts receivable 64,059 58,834
Inventories 82,134 65,674
Deferred taxes, current portion, net 1,656 1,710
Income tax receivable, net 17,023 1,357
Prepaid expenses and other current assets 24,424 24,101
Total current assets 405,811 432,175
Property, plant and equipment, net 315,489 313,979
In-process research and development 77,800 77,800
Intangible assets, net 56,202 58,344
Goodwill 41,984 41,984
Deferred tax assets, long-term, net  12,863 12,764
Other assets 7,696 8,216
Total assets  $ 917,845  $ 945,262
LIABILITIES AND STOCKHOLDERS' EQUITY    
Current liabilities:    
Accounts payable  $ 40,583  $ 40,930
Accrued expenses and other current liabilities 4,606 6,274
Accrued compensation 20,818 31,654
Contingent consideration, current portion 6,860 6,487
Provisions for chargebacks 2,164 2,246
Deferred revenue, current portion 5,266 5,345
Total current liabilities 80,297 92,936
Contingent consideration, net of current portion 41,594 41,170
Long-term indebtedness 251,000 251,000
Deferred revenue, net of current portion 5,806 5,713
Other liabilities 1,270 1,242
Total liabilities 379,967 392,061
Commitments and contingencies    
Stockholders' equity:    
Preferred stock, $0.001 par value; 15,000,000 shares authorized, 0 shares issued and outstanding at March 31, 2015 and December 31, 2014, respectively  --   -- 
Common stock, $0.001 par value; 100,000,000 shares authorized, 38,745,536 shares issued and 38,325,347 shares outstanding at March 31, 2015; 38,129,872 shares issued and 37,709,683 shares outstanding at December 31, 2014 38 38
Treasury stock, at cost, 420,189 common shares for both March 31, 2015 and December 31, 2014 (6,320) (6,320)
Additional paid-in capital 280,653 274,222
Accumulated other comprehensive loss (3,242) (3,008)
Retained earnings 266,749 288,269
Total stockholders' equity  537,878 553,201
Total liabilities and stockholders' equity   $ 917,845  $ 945,262
 
Emergent BioSolutions Inc. and Subsidiaries
Consolidated Statements of Operations
(in thousands, except share and per share data)
     
  Three Months Ended March 31,
  2015 2014
  (Unaudited)
Revenues:    
Product sales  $ 18,291  $ 35,767
Contract manufacturing 12,243 2,726
Contracts, grants and collaborations 33,099 15,391
Total revenues 63,633 53,884
     
Operating expense:    
Cost of product sales and contract manufacturing 18,748 18,997
Research and development 38,702 30,256
Selling, general and administrative 34,493 30,089
Loss from operations (28,310) (25,458)
     
Other income (expense):    
Interest income 82 40
Interest expense (1,661) (3,535)
Other income (expense), net 100 512
Total other income (expense) (1,479) (2,983)
     
Loss before benefit from income taxes  (29,789) (28,441)
Benefit from income taxes  (8,269) (8,205)
Net loss  $ (21,520)  $ (20,236)
     
Loss per share - basic  $ (0.57)  $ (0.55)
Loss per share - diluted  $ (0.57)  $ (0.55)
     
Weighted-average number of shares - basic 37,949,358 36,854,370
Weighted-average number of shares - diluted 37,949,358 36,854,370
 
Emergent BioSolutions Inc. and Subsidiaries
Consolidated Statements of Cash Flows
(in thousands)
     
  Three Months Ended March 31, 
  2015 2014
Cash flows from operating activities: (Unaudited)
     
Net loss $ (21,520) $ (20,236)
Adjustments to reconcile to net cash used in operating activities:     
Stock-based compensation expense 3,798 2,650
Depreciation and amortization 8,532 6,835
Current and deferred incomes taxes (7,261) (8,052)
Change in fair value of contingent consideration 1,559 412
Write off of debt issuance costs  --  1,831
Excess tax benefits from stock-based compensation (5,414) (4,570)
Other 17 453
Changes in operating assets and liabilities:    
Accounts receivable (5,225) 17,590
Inventories (16,460) (4,006)
Income taxes (12,160) (3,753)
Prepaid expenses and other assets (249) 556
Accounts payable 1,102 (10,713)
Accrued expenses and other liabilities (1,641) 1,546
Accrued compensation (10,883) (8,720)
Provision for chargebacks (82) 159
Deferred revenue 14 (1,227)
Net cash used in operating activities (65,873) (29,245)
Cash flows from investing activities:    
Purchases of property, plant and equipment (9,082) (4,590)
Acquisition of Cangene Corporation, net of acquired cash  --  (178,167)
Net cash used in investing activities (9,082) (182,757)
Cash flows from financing activities:    
Proceeds from convertible debenture, net of bank fees  --  241,654
Proceeds from long-term debt obligations  --  1,000
Issuance of common stock upon exercise of stock options 6,344 8,137
Excess tax benefits from stock-based compensation 5,414 4,570
Principal payments on long-term indebtedness  --  (62,000)
Contingent obligation payments (762) (487)
Net cash provided by financing activities 10,996 192,874
     
Effect of exchange rate changes on cash and cash equivalents (25) 5
     
Net decrease in cash and cash equivalents (63,984) (19,123)
Cash and cash equivalents at beginning of period 280,499 179,338
Cash and cash equivalents at end of period  $ 216,515  $ 160,215

Investor Contact Robert G. Burrows Vice President, Investor Relations 301-795-1877 Media Contact: Tracey Schmitt Vice President, Global Public Affairs and Corporate Responsibility 301-795-1800

Scroll down for more posts ▼

Top 10 Most Recent News Articles

AR Cards in Casino Gaming: A High-Stakes Revolution

Updated Category News Views 13

A New Breed of Casino Experience Walk into a casino today, and you might just enter a whole new reality. No, this isn’t a cheesy magician’s trick or a glitzy PR stunt—this is the real deal brought to you by augmented reality (AR) trading cards. Imagine the slots you love wrapped in a sci-fi movie where characters leap out, tap you on the shoulder, and call you by...

Continue Reading
Nevada Expands Rural Youth Mental Health Access

Updated Category News Views 148

Nevada's Rural Mental Health Crisis When you're navigating the barren stretches of rural Nevada, the scenic views can be breathtaking. But for many families, finding basic services like mental health care is as challenging as striking water in the desert. Cartwheel Care has taken the bull by the horns with their latest initiative to bridge this glaring gap. Partnering...

Continue Reading
HKEX Unveils New Offshore RMB Bond Index

Updated Category News Views 221

Here's the scoop: Hong Kong Exchanges and Clearing Limited (HKEX) just rolled out something worth eyeing—the HKEX Offshore RMB Bond Index. It's the first of its kind from HKEX, catered to those Dim Sum bonds floating around in the city. With Bloomberg lending a hand on the index smarts, this step is poised to give Hong Kong a leg up in the global financial marathon....

Continue Reading
Akeso's Gumokimab Wins NMPA Approval for AS Treatment

Updated Category News Views 199

Gumokimab Approved: A New Dawn in AS Treatment Yeah, the biotech world shifts gears today as Akeso's gumokimab received the green light from China's National Medical Products Administration (NMPA). This approval for treating ankylosing spondylitis, or AS, isn't just another checkbox for Akeso; it's a game-changer in tackling this chronic inflammatory disease. Why should...

Continue Reading
Lululemon Faces Class Action over Alleged Missteps

Updated Category News Views 39

Trouble Brewing for Lululemon Y'ever get that gut feeling when something doesn't smell right? Well, Lululemon Athletica (NASDAQ: LULU) investors are probably feeling that now. A class action's kicking up dust over what some are saying was a downright bumpy ride. The brainiacs at Robbins LLP urge those who've lost bucks riding the LULU train to step forward ahead of the...

Continue Reading
Exploring Creation: A Fresh Look at Genesis

Updated Category News Views 67

Opening Up Genesis in a New Light Hey, if you’re like most folks, you’ve probably heard Genesis framed as the battleground for science versus religion debates, right? Enter into this mix a fresh take with Robert E. Franzen’s new book, The Narration of Creation. This book asks you to overlook those grand philosophical fights and instead focus on the narrative itself....

Continue Reading
Pollo AI Unveils York AI: Automating Social Growth

Updated Category News Views 278

York AI Debuts as the New Kid on the Block Amid the hustle and bustle of a tech-savvy Singapore, Pollo AI’s latest offering, York AI, sashays onto the scene with the promise of putting social media growth on cruise control. We're talking about a digital sidekick that seems to know your online persona better than you do. It’s tailored for everyone from the small-time...

Continue Reading
AdMaven's Mave AI: Revolutionizing Campaign Management

Updated Category News Views 106

Taking the Tedious Out of Advertising You've got to love it when technology actually makes life easier, rather than more complicated. AdMaven's latest fancy toy, the AI assistant Mave, is promising just that. It's designed to take the heavy lifting off advertisers' shoulders, especially the day-to-day grind of tweaking ad settings and monitoring performance. If you've...

Continue Reading
Portillo's Faces Legal Heat: Investor Class Action Filed

Updated Category News Views 53

What’s Eating Portillo's? Ah, once upon a misstep in the land of promising expansion, now we have Portillo's Inc. (NASDAQ: PTLO) neck-deep in legal hot water. Those golden fries and famous sandwiches somehow didn't pave the way for stockholder bliss. Why the turmoil? On an ordinary November morning, the DJS Law Group made it clear: They're rallying the troops for a...

Continue Reading
Trades Workforce Shortage Costs Wallop U.S. Economy

Updated Category News Views 83

The Forgotten Backbone of America Don't sleep on this: America's got itself a trade worker crisis, and it's not just a numerical hiccup. We’re down nearly 1.9 million skilled trades workers, and that's a gut punch to the economy—a hefty $1.2 billion a day in GDP loss. These are the folks who keep the wheels greased, the lights on, and the goods flowing. Without them,...

Continue Reading

Top 5 Most Recently Viewed Articles

boberdoo Launches Dynamic Consent for Enhanced User Privacy

Updated Category News Views 92

boberdoo's Innovative Approach to One-to-One Consent boberdoo is making waves with its Dynamic Consent solution, a vital tool for businesses looking to comply with the FCC's one-to-one consent regulation. This live solution has been available since May 2024 and is designed to enhance transparency in lead generation by allowing consumers to have a voice in which companies...

Continue Reading
Understanding the Recent Private Student Loan Trends and Insights

Updated Category News Views 254

Overview of Recent Trends in Private Student Loans In the recent semi-annual Private Student Loan Report released by Enterval Analytics, insights into the current status of private student loans reveal a stable repayment landscape. Since Enterval focuses on the private student loan market, their findings shed light on how borrowers are adapting their financial strategies...

Continue Reading
Kyocera Unveils Exclusive Knife Set Celebrating 40 Years of Innovation

Updated Category News Views 62

Kyocera celebrated four decades of pushing boundaries in ceramic cutlery, revealing an exclusive two-piece knife set designed for both chefs and home cooks. The knives—a 4.5-inch Utility and a 5.5-inch Santoku—come dressed in vibrant Aegean Blue or Botanical Green and carry a price tag of $85. This limited-edition release is set to hit select retailers by late fall...

Continue Reading
PTC Plans Conference Call for Upcoming Fiscal Q1 Results

Updated Category News Views 145

PTC to Hold Fiscal Q1 Conference Call Boston, January 2026 — PTC (NASDAQ: PTC) is gearing up to unveil its financial performance for the first quarter of fiscal year 2026 on February 4. Investors and interested parties are invited to join a conference call and webcast at 5 PM Eastern Time, right after the stock market closes. This event will provide valuable insights...

Continue Reading
Moke America Unveils Enhanced Electric Street Vehicle for All

Updated Category News Views 282

Introducing the New Electric Street-Legal Moke Moke America, the beloved electric vehicle manufacturer, has taken a bold step forward with the launch of its latest street-legal Moke. Previously classified as a Low Speed Vehicle, this newly upgraded Moke can now reach an impressive top speed of 45 MPH, transforming the driving experience into something truly exhilarating....

Continue Reading